The FDA grant provides third-party validation and non-dilutive capital, but the stock impact will depend on Phase 1 data readouts. Monitor for trial initiation in Q1 2027 and any interim efficacy or safety updates.
Price Chart
Executive Summary
Marker Therapeutics announced it was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials Grants program to support a Phase 1 study of its lead MAR-T cell therapy, MT-601, in locally advanced unresectable pancreatic cancer. The non-dilutive funding provides external validation of the platform's scientific rationale and extends the company's cash runway, with clinical initiation expected in Q1 2027.
Key Facts
- Awarded $2.6 million FDA Orphan Products Clinical Trials grant for MT-601 in pancreatic cancer
- FDA received 66 applications and selected 6 projects for funding in fiscal year 2026
- Clinical initiation of the pancreatic cancer study expected in Q1 2027
- Prior Phase 1/2 Baylor study showed 84.6% disease control rate and 14.1 month median overall survival
- Non-dilutive funding adds to existing NIH SBIR and CPRIT grants for the pancreatic cancer program
Financial Impact
$2.6 million non-dilutive grant from the FDA
Risk Factors
- Phase 1 trial may fail to replicate prior Baylor study results
- Pancreatic cancer is a difficult indication with high historical failure rates
- Company remains a clinical-stage biotech with no approved products and limited financial resources
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-116720 |
| Document: tm2627740d1_ex99-1.htm | 0001104659-26-116720 |
| Document: 0001104659-26-116720-index-headers.html | 0001104659-26-116720 |
| Document: 0001104659-26-116720-index.html | 0001104659-26-116720 |
| Document: 0001104659-26-116720.txt | 0001104659-26-116720 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $1.20 $1.16 | ▼ −3.33% | ▼ −3.67% | $0.9600 (−20.00%) |
Oct 19, 2026 7d ago | Press Release | $1.20 $1.16 | ▼ −3.33% | ▼ −3.67% | $0.9600 (−20.00%) |
Mar 20, 2026 31w ago | DEFA14A | $1.31 $1.26 | ▼ −3.82% | ▼ −3.46% | $0.9600 (−26.72%) |
Mar 19, 2026 31w ago | 8-K | $1.32 $1.34 | ▲ +1.52% | ▲ +3.26% | $0.9600 (−27.27%) |
Mar 18, 2026 31w ago | Press Release | $1.32 $1.34 | ▲ +1.52% | ▲ +3.26% | $0.9600 (−27.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers